Comparative Pharmacology
Head-to-head clinical analysis: ARANESP versus EPOGEN PROCRIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARANESP versus EPOGEN PROCRIT.
ARANESP vs EPOGEN/PROCRIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aranesp (darbepoetin alfa) is an erythropoiesis-stimulating agent (ESA) that stimulates erythropoiesis by binding to the erythropoietin receptor on erythroid progenitor cells, promoting their survival, proliferation, and differentiation into mature red blood cells.
Erythropoiesis-stimulating agent that binds to and activates the erythropoietin receptor on erythroid progenitor cells, stimulating proliferation and differentiation into mature red blood cells.
Initial dose 0.45 mcg/kg intravenously or subcutaneously once weekly; for patients converting from epoetin alfa, see prescribing information for dose conversion.
50-100 units/kg intravenously or subcutaneously three times weekly. Initial dose 50 units/kg three times weekly; adjust to maintain hemoglobin target (usually 10-12 g/dL).
None Documented
None Documented
The terminal elimination half-life is approximately 21 hours (range 15-30 hours) in patients with chronic kidney disease following intravenous administration, and 49 hours (range 27-89 hours) after subcutaneous administration. The long half-life allows for less frequent dosing compared to epoetin alfa.
Terminal half-life: ~4-13 hours in healthy subjects; prolonged to 13-28 hours in chronic kidney disease or on dialysis (due to reduced clearance).
Renal clearance accounts for approximately 10% of total body clearance; however, darbepoetin alfa is primarily eliminated via receptor-mediated endocytosis and subsequent intracellular degradation. Less than 5% is excreted unchanged in urine.
Primarily hepatic metabolism; ~10% excreted unchanged in urine. Fecal elimination negligible.
Category C
Category C
Erythropoiesis-Stimulating Agent
Erythropoiesis-Stimulating Agent